Syncona completes sale of Gyroscope to Novartis
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Subscribe To Our Newsletter & Stay Updated